Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Atzpodien

Showing results (111-120 of 116) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 116 results.
British Journal of Cancer|March 1, 2002
Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)J Atzpodien, K Neuber, D Kamanabrou, et al.
British Journal of Cancer|April 16, 2002
CXCR4/CXCL12 expression and signalling in kidney cancerA J Schrader, O Lechner, M Templin, et al.
British Journal of Cancer|August 16, 2006
Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)J Atzpodien, H Kirchner, U Rebmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2004
Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)J Atzpodien, H Kirchner, U Jonas, et al.
Journal of Cancer Research and Clinical Oncology|May 26, 2020
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)A Kurreck, M Geissler, U M Martens, et al.
International Journal of Cancer|February 6, 1999
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1M Marchand, N van Baren, P Weynants, et al.
Pageof 12

Showing results (111-120 of 116) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 116 results.
British Journal of Cancer|March 1, 2002
Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)J Atzpodien, K Neuber, D Kamanabrou, et al.
British Journal of Cancer|April 16, 2002
CXCR4/CXCL12 expression and signalling in kidney cancerA J Schrader, O Lechner, M Templin, et al.
British Journal of Cancer|August 16, 2006
Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)J Atzpodien, H Kirchner, U Rebmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2004
Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)J Atzpodien, H Kirchner, U Jonas, et al.
Journal of Cancer Research and Clinical Oncology|May 26, 2020
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)A Kurreck, M Geissler, U M Martens, et al.
International Journal of Cancer|February 6, 1999
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1M Marchand, N van Baren, P Weynants, et al.
Pageof 12